Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01FX18
|
| gptkbp:brand |
gptkb:Tepezza
|
| gptkbp:CASNumber |
1309640-32-3
|
| gptkbp:developer |
gptkb:Horizon_Therapeutics
|
| gptkbp:drugClass |
antineoplastic agent
|
| https://www.w3.org/2000/01/rdf-schema#label |
Teprotumumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
IGF-1R antagonist
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
hearing impairment
nausea diarrhea fatigue alopecia muscle spasm |
| gptkbp:target |
insulin-like growth factor-1 receptor
|
| gptkbp:UNII |
6X9OC3H4PE
|
| gptkbp:usedFor |
thyroid eye disease
|
| gptkbp:bfsParent |
gptkb:Genmab
gptkb:Genmab_A/S |
| gptkbp:bfsLayer |
7
|